Utilization management programs for atopic dermatitis may hinder patient care, causing treatment delays and increased costs despite advances in biologic therapies.
Jeffery D. Dunn, PharmD, MBA
Advertisement
Articles by Jeffery D. Dunn, PharmD, MBA
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Dermatology Times
1
Ritlecitinib Meets Co-Primary End Points in Phase 3 Nonsegmental Vitiligo Trials
2
Evidence-Based Best Practices for Melasma Care
3
BBT001 Bispecific Antibody Demonstrates Fast AD Clearance and Long-Lasting Itch Relief in Phase 1 Trial
4
The Aesthetic Edge: July 2026
5